Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare, Inc. reported an insider equity award for Chief Medical Officer and director William Frazier. On January 19, 2026, he received 11,690 Restricted Stock Units (RSUs), each representing a contingent right to one common share. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
On the same date, he was also granted 2,922 Phantom Share Units under the company’s Phantom Share Unit Plan. Each phantom share represents the right to receive the cash value of one common share, determined based on the share price on the vesting date, and also vests in three equal annual installments starting one year after the grant date.
Viemed Healthcare President Michael Moore reported equity compensation and related share settlements. On January 19, 2026, he received 118,759 Restricted Stock Units and 29,690 phantom share units, each representing the value of one common share and vesting in three equal annual installments beginning on the first anniversary of the grant date. Earlier, on January 17, 2026, previously granted RSUs and phantom units vested, resulting in the acquisition and disposition of matching common shares, including 8,548 shares withheld at $7.33 per share to cover taxes. After these transactions, Moore directly beneficially owned 144,734 common shares and indirectly owned 1,722,614 common shares through Moore Faster LLC.
Viemed Healthcare, Inc. reported insider equity activity for Chief Operating Officer and director William Todd Zehnder. On January 19, 2026, he received 118,759 Restricted Stock Units (RSUs) and 29,690 phantom share units, each tied to one common share or its cash value and vesting in three equal annual installments beginning one year after the grant date.
On January 17, 2026, previously granted awards from January 17, 2023 partially vested. This led to the acquisition of 26,939 common shares from RSUs and 6,735 common shares tied to cash-settled phantom shares, followed by dispositions back to the company. The filing also shows 8,550 common shares withheld at $7.33 per share to cover taxes. After these transactions, Zehnder directly held 292,362 common shares, plus the new RSU and phantom unit balances.
Viemed Healthcare vice president of sales Jerome Cambre reported equity compensation and related tax transactions in company stock. On January 17, 2026, previously granted awards vested, resulting in the acquisition of 8,525 common shares from restricted stock units and 2,132 common shares tied to phantom share units. To cover taxes from the vesting, 2,784 shares and a separate 2,132-share block were disposed of at a per-share value of $7.33, leaving Cambre with 89,932 common shares held directly.
On January 19, 2026, Cambre received new grants of 40,676 restricted stock units and 10,169 phantom share units. Each restricted stock unit represents a contingent right to receive one common share, and both the new RSU and phantom share awards vest in three equal annual installments beginning on the first anniversary of their respective grant dates.
Viemed Healthcare (VMD) Chief Financial Officer Trae Fitzgerald reported a mix of equity awards vesting, tax withholding, and new grants. On January 17, 2026, 9,590 restricted stock units and 2,397 cash-settled phantom share units vested, each unit economically equal to one common share. To cover taxes from RSU vesting, 3,132 common shares were withheld at $7.33 per share, based on the January 16, 2026 closing price, and 2,397 common shares were delivered back to the company in connection with phantom share settlement. After these transactions, Fitzgerald directly held 89,452 common shares.
On January 19, 2026, Fitzgerald received new equity awards of 46,662 restricted stock units and 11,666 phantom share units, each with a stated value of $0 per unit on grant and scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.
Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity compensation transactions. On January 17, 2026, 4,884 restricted stock units and 1,221 cash-settled phantom share units vested, resulting in the acquisition of the same number of common shares. To cover tax obligations tied to the RSU vesting, 1,595 common shares were withheld at a per share value of $7.33, leaving 28,792 common shares held directly after the transactions.
On January 19, 2026, Trahan was granted 50,360 new restricted stock units and 12,590 phantom share units. Both awards vest in three equal annual installments beginning on the first anniversary of their grant date. Each RSU represents a right to receive one common share, while each phantom share represents the cash value of one common share on the vesting date.
Viemed Healthcare, Inc. reported a Third Amendment to its Credit Agreement with Regions Bank and other lenders. The change extends the Borrower’s delayed draw term loan commitment expiration date to November 29, 2026, from November 29, 2025, with additional technical amendments. This keeps the facility available for an extra year under the amended terms.
The company also made an Investor Deck Presentation available and may use it in discussions with investors and analysts. As indicated, this presentation and related Item 7.01 information are furnished, not filed, under the Exchange Act.
Viemed Healthcare (VMD) reported Q3 results showing continued top-line growth alongside active capital deployment. Revenue reached $71.9 million, up from $58.0 million a year ago, driven by ventilator rentals and expanding equipment sales and services. Gross profit was $41.3 million versus $34.4 million. Net income attributable to the company was $3.5 million (diluted EPS $0.09) compared with $3.9 million (EPS $0.10) last year as operating costs rose with growth and integration.
Year-to-date, revenue totaled $194.1 million vs. $163.6 million, and diluted EPS was $0.23 vs. $0.17. Operating cash flow was strong at $33.5 million. The company closed the Lehan Drugs acquisition on July 1 for $28.7 million, adding goodwill of $25.5 million. Debt increased under the 2022 facilities to $21.1 million from $4.6 million at year-end, while cash ended the quarter at $11.1 million. Viemed repurchased 1,976,441 shares for $13.6 million under its 2025 program, reducing the quarter-end share count to 38,017,907. On October 29, the company repaid $5.0 million on its revolver.
Viemed Healthcare (VMD) furnished an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The company provided a press release and a Financial Supplement as exhibits.
The materials are furnished under Item 2.02 and, under General Instruction B.2, are not deemed filed or subject to Section 18 liabilities. Exhibits include the press release (99.1) and Financial Supplement (99.2), both dated November 5, 2025.
Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Viemed Healthcare, Inc. announced on September 23, 2025 that it has completed its previously authorized share repurchase program. The company repurchased a total of 1,976,441 common shares for an aggregate purchase price of approximately $13.2 million, before applicable taxes. The announcement was issued via a press release furnished as Exhibit 99.1 to the Current Report and is incorporated by reference. The filing notes the press release and related Item 7.01 information are furnished and not "filed" for purposes of Section 18 of the Exchange Act.